PILA PHARMA’s Post

Gland Pharma’s European acquisition—made over a year ago—has been a dud, despite the positive spin the injectables maker has tried to put on it. Can the new CEO, set to join in January 2025, turn things around for Gland Pharma? NEETHI LISA ROJAN investigates. https://lnkd.in/dQnRqDYX

#NewsAroundtheNetwork Partner Daniel Rosenberg at Charles Russell Speechlys, ALFA International's member firm in the United Kingdom, Bahrain and France, led his team in providing guidance to SAI MedPartners for the acquisition of IDEA Pharma. Read more here: https://bit.ly/3CZjnFO

Every journey has its defining moments, and ours is a story of coming full circle. From the founding of Matrix Laboratories, through the transformative chapter with Viatris, and now returning to our roots as Matrix Pharma Corp, our journey is a testament to resilience, growth, and unyielding commitment. With every step, we’ve not only evolved but elevated the standards of innovation and collaboration in the pharmaceutical world. Each chapter has shaped our present, fortifying a future grounded in quality, passion, and a shared vision of creating excellence together. Today, as Matrix Pharma Corp, we stand stronger than ever, ready to write the next chapter of our legacy – one that honours the past and embraces the future with renewed determination.

Seriously- I love what I do! Here is why. Strategic and collaborative partnerships are anchored in knowing what is most important to your stakeholders. Goals- successes-opportunities—barriers and pain points—understanding them is all part of a good partnership. The 3rd Chief Commercial Officer Summit provided such amazing insights and showcased why we at Amplity Health believe in the approach of co-developing commercial solutions with our #pharma and #biotech partners 👏🏾 Some key insights and takeaways from the summit (not exhaustive!). So many good ones! ✨Commercial must come in earlier (compliantly) in the process. The value proposition and positioning work will be a bit easier down the line! ✨Successful CCOs, especially launching in Rare Disease are Agile and Adaptive ✨Different size companies face different challenges. Know what they are, mitigate them early and strategically ✨The people, culture, and relationships you build (and HOW you build them) with your team and X-functional partners can have significant impact on how well you hit your end goals! ✨You can’t cut corners on Insights, especially Patient Journey and Market Access insights heading into phase 3! Bradie Paul (she/her) #DGEEvents #commercialsstrategy #startegicpartnerships #chiefcommercialofficers #commercialexcellence #strategyandexecution

Welcome Lyfegen! We are thrilled to announce that TX Ventures has led a CHF 5 million Series A financing round in Lyfegen. In the face of rising drug costs and increasingly complex rebate agreements, the company has developed a fully automated software solution that streamlines global drug rebate operations for healthcare payers and pharmaceutical companies. With this new funding, Lyfegen will further accelerate its growth and expand beyond the European market. We look forward to working with Girisha Fernando, Michel Mohler, Nico Julian Mros, Andrei Ghiordun and the entire Lyfegen team on this journey. Co-investors in the round include aMoon Fund and other institutional investors. Read more on our website: https://lnkd.in/dK3TurGw Jens Schleuniger Krzysztof Bialkowski Klaudia Kasperczyk Daniel Mönch Dr. Ulrich Schmitt Miriam Wohlfarth Olivier Rihs Andreas Schneider 🌱 Ewan Jones Ivan Sharogh Muneton Gil #fintech #VC #SeriesA #Europe #Healthcare #Pharma #DrugRebates

hVIVO, the Irish trailblazer in pharmaceutical services, has just hit a new milestone, selling nearly 30 million placing shares and raising a whopping £8.4 million (€9.8 million)! 🌟 This strategic move, aimed at satisfying the surging institutional demand, underscores the immense confidence investors have in hVIVO's potential and direction. 📈💡 With the sale representing about 4.4% of the company's share capital, Hvivo demonstrates not just its market prowess but also its commitment to expanding its influential role in testing infectious and respiratory disease products. 🧪🔬 This significant financial boost is set to further empower Hvivo as it continues to innovate and lead in the pharmaceutical services sector, reinforcing Ireland's position as a key player in the global life sciences ecosystem. 🇮🇪💚 #PharmaceuticalServices #InvestmentGrowth #HanleyAutomation

After years of underperformance, the pharma industry is seeing a steady pickup in M&A activity. Life Sciences and M&A partner Nicole Daley shares her thoughts on portfolio diversification and additive dealmaking, and on how companies with a sharper focus can be more appealing to investors in the life sciences arena with PharmaVoice. Read more below. #LifeSciences #M&A #Pharma

Stephenson Harwood has advised the management team of EMAS Pharma on Kester Capital's acquisition and MBI of EMAS Pharma, a leading clinical research organisation.   Partner Chris Manning led the team, supported by managing associate Alex Stevens and associate Jessica Martin. Further support was provided by employment partner Richard Freedman and associate Dermot Neligan. Read more here: https://lnkd.in/d5TtPdXe #PrivateCapitalandFunds #LifeSciencesandHealthcare

After years of underperformance, the pharma industry is seeing a steady pickup in M&A activity. Life Sciences and M&A partner Nicole Daley shares her thoughts on portfolio diversification and additive dealmaking, and on how companies with a sharper focus can be more appealing to investors in the life sciences arena with PharmaVoice. Read more below. #LifeSciences #M&A #Pharma

KKR, a global investment firm, agreed to acquire a stake in Immedica Pharma AB, a pharmaceutical company, from Impilo, a Nordic healthcare investment firm. Financial terms were not disclosed. “The Immedica team is one of the best that we have encountered in a space that we have been following for some time. We are deeply impressed by the accomplishments of Immedica under Impilo’s ownership and the establishment of a rare disease player with a highly promising pipeline. We look forward to working with the management team alongside Impilo to accelerate growth further,” Kugan Sathiyanandarajah, KKR Partner and Head of Health Care Strategic Growth Europe. KKR (led by Kugan Sathiyanandarajah) is advised by ClearView Healthcare Partners, Alvarez & Marsal, Bank of America, PwC, Cooley LLP, Gibson Dunn , Setterwalls Advokatbyrå, FGS Global (led by Alastair Elwen) and Fogel & Partners (led by Ludvig Gauffin). Impilo (led by Josh Stein) is advised by Boston Consulting Group (BCG), Morgan Stanley, PwC, Latham & Watkins and Mannheimer Swartling. #MergersAcquisitionsDivestitures #Healthcare #Pharmaceuticals